|
1
|
Mao XY, Lee MJ, Zhu J, Zhu C, Law SM and
Snijders AM: Genome-wide screen identifies a novel prognostic
signature for breast cancer survival. Oncotarget. 8:14003–14016.
2017.PubMed/NCBI
|
|
2
|
Tsai M, Lo S, Audeh W, Qamar R, Budway R,
Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, et al:
Association of 70-gene signature assay findings with physicians'
treatment guidance for patients with early breast cancer classified
as intermediate risk by the 21-gene assay. JAMA Oncol.
4:e1734702018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Palmieri C and Jones A: The 2011 EBCTCG
polychemotherapy overview. Lancet. 379:390–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singh K, He X, Kalife ET, Ehdaivand S,
Wang Y and Sung CJ: Relationship of histologic grade and histologic
subtype with oncotype Dx recurrence score; retrospective review of
863 breast cancer oncotype Dx results. Breast Cancer Res Treat.
168:29–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Denkert C, von Minckwitz G, Brase JC, Sinn
BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD,
et al: Tumor-infiltrating lymphocytes and response to neoadjuvant
chemotherapy with or without carboplatin in human epidermal growth
factor receptor 2-positive and triple-negative primary breast
cancers. J Clin Oncol. 33:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Denkert C, Wienert S, Poterie A, Loibl S,
Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, et
al: Standardized evaluation of tumor-infiltrating lymphocytes in
breast cancer: Results of the ring studies of the international
immuno-oncology biomarker working group. Mod Pathol. 29:1155–1164.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dieci MV, Radosevic-Robin N, Fineberg S,
van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso
TM, Demaria S, Castaneda C, et al: Update on tumor-infiltrating
lymphocytes (TILs) in breast cancer, including recommendations to
assess TILs in residual disease after neoadjuvant therapy and in
carcinoma in situ: A report of the international immuno-oncology
biomarker working group on breast cancer. Semin Cancer Biol.
52:16–25. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horimoto Y, Hayashi T and Arakawa A:
Pathology of healing: What else might we look at? Cancer Med.
5:3586–3587. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dieci MV, Arnedos M, Delaloge S and Andre
F: Quantification of residual risk of relapse in breast cancer
patients optimally treated. Breast. 22 Suppl 2:S92–S95. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Demaria S, Volm MD, Shapiro RL, Yee HT,
Oratz R, Formenti SC, Muggia F and Symmans WF: Development of
tumor-infiltrating lymphocytes in breast cancer after neoadjuvant
paclitaxel chemotherapy. Clin Cancer Res. 7:3025–3030.
2001.PubMed/NCBI
|
|
13
|
Blok EJ, Engels CC, Dekker-Ensink G,
Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ,
Morden JP, Bliss JM, Coombes RC, et al: Exploration of
tumour-infiltrating lymphocytes as a predictive biomarker for
adjuvant endocrine therapy in early breast cancer. Breast Cancer
Res Treat. May 15–2018.(Epub ahead of print). View Article : Google Scholar
|
|
14
|
Dieci MV, Frassoldati A, Generali D,
Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F,
Michelotti A, Berardi R, et al: Tumor-infiltrating lymphocytes and
molecular response after neoadjuvant therapy for HR+/HER2- breast
cancer: Results from two prospective trials. Breast Cancer Res
Treat. 163:295–302. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohtani H, Mori-Shiraishi K, Nakajima M and
Ueki H: Defining lymphocyte-predominant breast cancer by the
proportion of lymphocyte-rich stroma and its significance in
routine histopathological diagnosis. Pathol Int. 65:644–651. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salgado R, Denkert C, Campbell C, Savas P,
Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J,
et al: Tumor-infiltrating lymphocytes and associations with
pathological complete response and event-free survival in
HER2-positive early-stage breast cancer treated with lapatinib and
trastuzumab: A secondary analysis of the NeoALTTO trial. JAMA
Oncol. 1:448–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsoutsou PG, Bourhis J and Coukos G:
Tumor-infiltrating lymphocytes in triple-negative breast cancer: A
biomarker for use beyond prognosis? J Clin Oncol. 33:1297–1298.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garcia-Teijido P, Cabal ML, Fernández IP
and Pérez YF: Tumor-infiltrating lymphocytes in triple negative
breast cancer: The future of immune targeting. Clin Med Insights
Oncol. 10 Suppl 1:31–39. 2016.PubMed/NCBI
|
|
20
|
Pruneri G, Gray KP, Vingiani A, Viale G,
Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L,
Goldhirsch A, et al: Tumor-infiltrating lymphocytes (TILs) are a
powerful prognostic marker in patients with triple-negative breast
cancer enrolled in the IBCSG phase III randomized clinical trial
22–00. Breast Cancer Res Treat. 158:323–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ingold Heppner B, Untch M, Denkert C,
Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch
H, Solbach C, et al: Tumor-infiltrating lymphocytes: A predictive
and prognostic biomarker in neoadjuvant-treated HER2-positive
breast cancer. Clin Cancer Res. 22:5747–5754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hida AI, Sagara Y, Yotsumoto D, Kanemitsu
S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y and Ohi Y:
Prognostic and predictive impacts of tumor-infiltrating lymphocytes
differ between Triple-negative and HER2-positive breast cancers
treated with standard systemic therapies. Breast Cancer Res Treat.
158:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chung YR, Kim HJ, Jang MH and Park SY:
Prognostic value of tumor infiltrating lymphocyte subsets in breast
cancer depends on hormone receptor status. Breast Cancer Res Treat.
161:409–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jang N, Kwon HJ, Park MH, Kang SH and Bae
YK: Prognostic value of tumor-infiltrating lymphocyte density
assessed using a standardized method based on molecular subtypes
and adjuvant chemotherapy in invasive breast cancer. Ann Surg
Oncol. 25:937–946. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ogiya A, Yamazaki K, Horii R, Shien T,
Horimoto Y, Masuda N, Inao T, Hosoda M, Ishida N, Osako T, et al:
Post-relapse survival in patients with the early and late distant
recurrence in estrogen receptor-positive HER2-negative breast
cancer. Breast Cancer. 24:473–482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamashita H, Ogiya A, Shien T, Horimoto Y,
Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, et al:
Clinicopathological factors predicting early and late distant
recurrence in estrogen receptor-positive, HER2-negative breast
cancer. Breast Cancer. 23:830–843. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miyoshi Y, Shien T, Ogiya A, Ishida N,
Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, et
al: Differences in expression of the cancer stem cell marker
aldehyde dehydrogenase 1 among estrogen receptor-positive/human
epidermal growth factor receptor type 2-negative breast cancer
cases with early, late, and no recurrence. Breast Cancer Res.
18:732016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kotoula V, Chatzopoulos K, Lakis S,
Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H,
Galani E, Efstratiou I, et al: Tumors with high-density tumor
infiltrating lymphocytes constitute a favorable entity in breast
cancer: A pooled analysis of four prospective adjuvant trials.
Oncotarget. 7:5074–5087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dieci MV, Criscitiello C, Goubar A, Viale
G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S,
Curigliano G and Andre F: Prognostic value of tumor-infiltrating
lymphocytes on residual disease after primary chemotherapy for
triple-negative breast cancer: A retrospective multicenter study.
Ann Oncol. 25:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Watanabe T, Hida AI, Inoue N, Imamura M,
Fujimoto Y, Akazawa K, Hirota S and Miyoshi Y: Abundant tumor
infiltrating lymphocytes after primary systemic chemotherapy
predicts poor prognosis in estrogen receptor-positive/HER2-negative
breast cancers. Breast Cancer Res Treat. 168:135–145. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang K, Shen T, Siegal GP and Wei S: The
CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host
interface has prognostic value in triple-negative breast cancer.
Hum Pathol. 69:110–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tu MM, Rahim MMA, Sayed C, Mahmoud AB and
Makrigiannis AP: Immunosurveillance and immunoediting of breast
cancer via Class I MHC receptors. Cancer Immunol Res. 5:1016–1028.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsang JY, Au WL, Lo KY, Ni YB, Hlaing T,
Hu J, Chan SK, Chan KF, Cheung SY and Tse GM: PD-L1 expression and
tumor infiltrating PD-1+ lymphocytes associated with outcome in
HER2+ breast cancer patients. Breast Cancer Res Treat. 162:19–30.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stovgaard ES, Nielsen D, Hogdall E and
Balslev E: Triple negative breast cancer-prognostic role of
immune-related factors: A systematic review. Acta Oncol. 57:74–82.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nguyen L, Tosun AB, Fine JL, Lee AV,
Taylor DL and Chennubhotla SC: Spatial statistics for segmenting
histological structures in H&E stained tissue images. IEEE
Trans Med Imaging. 36:1522–1532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Semeraro M, Adam J, Stoll G, Louvet E,
Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy
N, et al: The ratio of CD8+/FOXP3 T lymphocytes
infiltrating breast tissues predicts the relapse of ductal
carcinoma in situ. Oncoimmunology. 5:e12181062016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Botti G, Collina F, Scognamiglio G, Rao F,
Peluso V, De Cecio R, Piezzo M, Landi G, De Laurentiis M, Cantile M
and Di Bonito M: Programmed death ligand 1 (PD-L1) tumor expression
is associated with a better prognosis and diabetic disease in
triple negative breast cancer patients. Int J Mol Sci. 18(pii):
E4592017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kochi M, Iwamoto T, Niikura N, Bianchini
G, Masuda S, Mizoo T, Nogami T, Shien T, Motoki T, Taira N, et al:
Tumour-infiltrating lymphocytes (TILs)-related genomic signature
predicts chemotherapy response in breast cancer. Breast Cancer Res
Treat. 167:39–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kotoula V, Lakis S, Vlachos IS,
Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D,
Aravantinos G, Efstratiou I, et al: Tumor infiltrating lymphocytes
affect the outcome of patients with operable triple-negative breast
cancer in combination with mutated amino acid classes. PLoS One.
11:e01631382016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Castaneda CA, Mittendorf E, Casavilca S,
Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C,
Dolores-Cerna K, et al: Tumor infiltrating lymphocytes in triple
negative breast cancer receiving neoadjuvant chemotherapy. World J
Clin Oncol. 7:387–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Loi S: Tumor-infiltrating lymphocytes,
breast cancer subtypes and therapeutic efficacy. Oncoimmunology.
2:e247202013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Maley CC, Koelble K, Natrajan R, Aktipis A
and Yuan Y: An ecological measure of immune-cancer colocalization
as a prognostic factor for breast cancer. Breast Cancer Res.
17:1312015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qian F, Qingping Y, Linquan W, Xiaojin H,
Rongshou W, Shanshan R, Wenjun L, Yong H and Enliang L: High
tumor-infiltrating FoxP3+ T cells predict poor survival
in estrogen receptor-positive breast cancer: A meta-analysis. Eur J
Surg Oncol. 43:1258–1264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Klauschen F, Müller KR, Binder A, Bockmayr
M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S,
et al: Scoring of tumor-infiltrating lymphocytes: From visual
estimation to machine learning. Semin Cancer Biol. 52:151–157.
2018. View Article : Google Scholar : PubMed/NCBI
|
